| GNW-Adhoc: Idorsia and Viatris successfully close the transaction for the global research and development collaboration |
| 18.03.2024 07:05:00 |
 |
^Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - March 18, 2024 Idorsia Ltd (SIX: IDIA) today announced that it has successfully closed the transaction with Viatris Inc. (NASDAQ: VTRS), a global healthcare company, for the global research and development collaboration, focused on the development and commercialization of two innovative compounds, selatogrel and cenerimod, discovered by Idorsia. The upfront consideration of USD 350 million has now been fully paid by Viatris to Idorsia. Further details will be provided with the combined Full Year 2023 and First Quarter 2024 financial reporting on April 25(th). The selatogrel and cenerimod programs will be discussed at an upcoming R&D day of our partner Viatris. Notes to the editor About Viatris Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on LinkedIn, Instagram, YouTube and X (formerly Twitter). About Idorsia Idorsia Ltd is reaching out for more - We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered near Basel, Switzerland - a European biotech-hub - Idorsia is specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options. Idorsia has a 20-year heritage of drug discovery, a broad portfolio of innovative drugs in the pipeline, an experienced team of professionals covering all disciplines from bench to bedside, and commercial operations in Europe and North America - the ideal constellation for bringing innovative medicines to patients. Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 800 highly qualified specialists dedicated to realizing our ambitious targets. For further information, please contact Andrew C. Weiss Senior Vice President, Head of Investor Relations & Corporate Communications Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil +41 58 844 10 10 investor.relations@idorsia.com (mailto:investor.relations@idorsia.com) media.relations@idorsia.com (mailto:media.relations@idorsia.com) www.idorsia.com (http://www.idorsia.com) The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward- looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. ° ISIN CH0363463438 AXC0050 2024-03-18/07:05 |
| Autor: - dpa-AFX |
| Copyright dpa-AFX Wirtschaftsnachrichten GmbH. Alle Rechte vorbehalten. Weiterverbreitung, Wiederveröffentlichung oder dauerhafte Speicherung ohne ausdrückliche vorherige Zustimmung von dpa-AFX ist nicht gestattet. |
| Österreich-Börsen | |||
| ATX | 4.189,54 | -10,48 | -0,25% |
| ATX Prime | 2.103,25 | -6,65 | -0,32% |
| Immobilien-ATX | 323,68 | -1,88 | -0,58% |
| Indizes | |||
| DAX | 22.567,14 | -109,27 | -0,48% |
| TecDax | 3.703,24 | -36,60 | -0,98% |
| MDAX | 28.470,09 | -215,64 | -0,75% |
| Dow Jones (EOD) | 41.350,93 | -82,55 | -0,20% |
| Nasdaq 100 | 19.358,79 | -237,23 | -1,21% |
| S & P 500 (EOD) | 5.599,30 | 27,23 | 0,49% |
| SMI | 12.836,19 | -32,24 | -0,25% |
|
|
| Zinsen / Währungen | |
 |
 |
| Wichtige Währungen | |||
| EUR/US$ | 1,0875 | -0,00 | -0,12% |
| EUR/Yen | 160,4577 | -0,96 | -0,60% |
| EUR/CHF | 0,9614 | 0,00 | 0,14% |
| EUR/Brit. Pfund | 0,8397 | -0,00 | -0,01% |
| Yen/US$ | 0,0068 | 0,00 | 0,50% |
| CHF/US$ | 1,1311 | -0,00 | -0,25% |
| Zinsen | |||
| ESTR (EUR) | 2,4120 | -0,25 | -9,43% |
| SAR® ON (CHF) | 0,4473 | 0,00 | 0,15% |
| TONA (JPY) | 0,4790 | 0,00 | 0,00 |
| Rohstoffe | |||
| baha Brent Indication | 69,49 | -0,77 | -1,10% |
| Gold | 2.970,08 | 48,03 | 1,64% |
| Silber | 33,16 | 0,11 | 0,32% |
| Platin | 980,25 | -5,25 | -0,53% |
